Carfilzomib promotes the osteogenic differentiation potential of mesenchymal stem cells derived from myeloma patients by inhibiting notch1 activity in vitro
机构：[a]Department of Hematology, Second Affiliated Hospital of Soochow University, Suzhou, Jiang Su 215004, PR China[b]Department of Cell Biology, Basic Medicine and Biology Science of Soochow University, Suzhou, Jiang Su 215004, PR Chinaa
signaling plays a key role in the differentiation of mesenchymal stem cells (MSCs). Carfilzomib(CFZ), a second-generation proteasome inhibitor, has potent cytotoxicity against myeloma cells. In this study, we investigated the effects of CFZ on the osteogenic differentiation potential of MSCs derived from myeloma patients (MM-MSCs) in vitro. MM-MSCs showed decreased osteogenic differentiation ability, together with an impairment of notch1 deactivation. The notch1 inhibitor DAPT and the downregulation of notch1 by shRNA promoted osteogenesis in MM-MSCs. Additionally, CFZ treatment resulted in notch1 inhibition and enhanced osteogenesis in MM-MSCs. These findings suggest that CFZ stimulates osteogenesis via notch1 inhibition. (C) 2014 Elsevier Ltd. All rights reserved.
基金：
supported by National Natural Science Foun-dation of China (No. 81172256; No. 81272631; No. 81102466), agrant from the Applied Basic Research Programs of Suzhou City(No. SYS201132), China Postdoctoral Science Foundation fundedproject (2014M550307 and 2014M551650), the Foundation forDoctors and Returned Scholars of Second Affiliated Hospital ofSoochow University (No. SDFEYBS1106), Jiangsu Province’s KeyMedical Department in 2011 and the Priority Academic ProgramDevelopment of Jiangsu Higher Education Institutions.
第一作者机构：[a]Department of Hematology, Second Affiliated Hospital of Soochow University, Suzhou, Jiang Su 215004, PR China
共同第一作者：
通讯作者：
通讯机构：[*]Department of Hematology, Second Affiliated Hospitalof Soochow University, No. 1055 Sanxiang Road, Suzhou, Jiang Su 215004, PR China.
推荐引用方式(GB/T 7714)：
Yali Li,Jun Li,Wenzhuo Zhuang,et al.Carfilzomib promotes the osteogenic differentiation potential of mesenchymal stem cells derived from myeloma patients by inhibiting notch1 activity in vitro[J].LEUKEMIA RESEARCH.2014,38(8):970-6.doi:10.1016/j.leukres.2014.05.022.
APA：
Yali Li,Jun Li,Wenzhuo Zhuang,Qian Wang,Xueping Ge...&Bingzong Li.(2014).Carfilzomib promotes the osteogenic differentiation potential of mesenchymal stem cells derived from myeloma patients by inhibiting notch1 activity in vitro.LEUKEMIA RESEARCH,38,(8)
MLA：
Yali Li,et al."Carfilzomib promotes the osteogenic differentiation potential of mesenchymal stem cells derived from myeloma patients by inhibiting notch1 activity in vitro".LEUKEMIA RESEARCH 38..8(2014):970-6
